Summary of FDA antibody-mediated rejection workshop P Archdeacon, M Chan, C Neuland, E Velidedeoglu, J Meyer, L Tracy, ... American journal of transplantation 11 (5), 896-906, 2011 | 203 | 2011 |
Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1–Infected patients: results of the clinical efficacy of resistance testing trial SA Wegner, MR Wallace, NE Aronson, SA Tasker, DL Blazes, ... Clinical infectious diseases 38 (5), 723-730, 2004 | 80 | 2004 |
Regulatory analysis of effects of hepatitis C virus NS5A polymorphisms on efficacy of elbasvir and grazoprevir TE Komatsu, S Boyd, A Sherwat, LR Tracy, LK Naeger, JO Julian, ... Gastroenterology 152 (3), 586-597, 2017 | 68 | 2017 |
Knowledge, attitudes, and practices related to Ebola virus disease at the end of a National Epidemic—Guinea, august 2015 MF Jalloh MMWR. Morbidity and Mortality Weekly Report 66, 2017 | 68 | 2017 |
Staphylococcus aureus Infections in US Veterans, Maryland, USA, 1999–20081 LRA Tracy, JP Furuno, AD Harris, M Singer, P Langenberg, ... Emerging infectious diseases 17 (3), 441, 2011 | 56 | 2011 |
Immune reconstitution following autologous transfers of CD3/CD28 stimulated CD4+ T cells to HIV-infected persons WB Bernstein, JH Cox, NE Aronson, LR Tracy, K Schlienger, S Ratto-Kim, ... Clinical immunology 111 (3), 262-274, 2004 | 34 | 2004 |
Estimating the impact of human papillomavirus (HPV) vaccination on HPV prevalence and cervical cancer incidence in Mali LR Tracy, HD Gaff, C Burgess, S Sow, PE Gravitt, JK Tracy Clinical infectious diseases 52 (5), 641-645, 2011 | 31 | 2011 |
Attitudes about vaccines to prevent Ebola virus disease in Guinea at the end of a large Ebola epidemic: Results of a national household survey KL Irwin, MF Jalloh, J Corker, BA Mahmoud, SJ Robinson, W Li, ... Vaccine 35 (49), 6915-6923, 2017 | 30 | 2017 |
Clinical development of therapeutic agents for hospitalized patients with influenza: challenges and innovations JC King, JH Beigel, MG Ison, RE Rothman, TM Uyeki, RE Walker, ... Open forum infectious diseases 6 (4), ofz137, 2019 | 24 | 2019 |
Characteristics of rare disease marketing applications associated with FDA product approvals 2006–2010 AR Pariser, DJ Slack, LJ Bauer, CA Warner, LRA Tracy Drug discovery today 17 (15-16), 898-904, 2012 | 22 | 2012 |
Chloroquine-azithromycin combination antimalarial treatment decreases risk of respiratory-and gastrointestinal-tract infections in Malawian children EA Gilliams, J Jumare, CW Claassen, PC Thesing, OM Nyirenda, ... The Journal of infectious diseases 210 (4), 585-592, 2014 | 20 | 2014 |
Generation of recombinant hyperimmune globulins from diverse B-cell repertoires SM Keating, RA Mizrahi, MS Adams, MA Asensio, E Benzie, KP Carter, ... nature biotechnology 39 (8), 989-999, 2021 | 17 | 2021 |
Omicron BA. 1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial IT Lee, CA Cosgrove, P Moore, C Bethune, R Nally, M Bula, PA Kalra, ... The Lancet Infectious Diseases 23 (9), 1007-1019, 2023 | 15 | 2023 |
Long-term clinical efficacy of resistance testing: results of the CERT trial S Wegner, M Wallace, S Tasker, N Aronson, D Blazes, C Tamminga, ... Antiviral Therapy 7, S170-S170, 2002 | 14 | 2002 |
Prescribing trends in us active duty service members with posttraumatic stress disorder: a population-based study from 2007-2013 G Loeffler, R Coller, LR Tracy, BR Derderian The Journal of Clinical Psychiatry 79 (4), 15309, 2018 | 12 | 2018 |
Predictive ability of positive clinical culture results and International Classification of Diseases, Ninth Revision, to identify and classify noninvasive Staphylococcus aureus … LRA Tracy, JP Furuno, AD Harris, M Singer, P Langenberg, ... Infection Control & Hospital Epidemiology 31 (7), 694-700, 2010 | 12 | 2010 |
Lack of blocking activity in anti-CTLA-4 antibodies reduces toxicity, but not anti-tumor efficacy EL Stone, KP Carter, EK Wagner, MA Asensio, E Benzie, YY Chiang, ... BioRxiv, 2021.07. 12.452090, 2021 | 11 | 2021 |
Racial disparity in all‐cause mortality among hepatitis C virus‐infected individuals in a general US population, NHANES III B Emmanuel, MD Shardell, L Tracy, S Kottilil, SS El‐Kamary Journal of viral hepatitis 24 (5), 380-388, 2017 | 10 | 2017 |
US FDA perspective on elbasvir/grazoprevir treatment for patients with chronic hepatitis C virus genotype 1 or 4 infection SD Boyd, LR Tracy, TE Komatsu, PR Harrington, P Viswanathan, J Murray, ... Clinical drug investigation 37, 317-326, 2017 | 10 | 2017 |
Switching people who smoke to unfiltered cigarettes: perceptions, addiction and behavioural effects in a cross-over randomised controlled trial K Pulvers, LR Tracy, TE Novotny, N Satybaldiyeva, A Hunn, DR Romero, ... Tobacco Control 32 (4), 520-523, 2023 | 9 | 2023 |